Consistent with a functional role for IDO1 expression in driving IBD-CRC development, mice treated with 1-L-MT had a significantly lower tumour number and tumour burden compared to mice treated with vehicle (Figs. 7B–D and S7A). Here, IDO1 is linked to colorectal carcinoma.